Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Endometrial cancer risk after fertility treatment: a population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sven-Eric Olsson
  • Susanne K Kjaer
  • Kristján Sigurdsson
  • Ole-Erik Iversen
  • Mauricio Hernandez-Avila
  • Cosette M Wheeler
  • Gonzalo Perez
  • Darron R Brown
  • Laura A Koutsky
  • Eng Hseon Tay
  • Patricia García
  • Kevin A Ault
  • Suzanne M Garland
  • Sepp Leodolter
  • Grace W K Tang
  • Daron G Ferris
  • Jorma Paavonen
  • Matti Lehtinen
  • Marc Steben
  • F Xavier Bosch
  • Joakim Dillner
  • Elmar A Joura
  • Slawomir Majewski
  • Nubia Muñoz
  • Evan R Myers
  • Luisa L Villa
  • Frank J Taddeo
  • Christine Roberts
  • Amha Tadesse
  • Janine Bryan
  • Roger Maansson
  • Scott Vuocolo
  • Teresa M Hesley
  • Alfred Saah
  • Eliav Barr
  • Richard M Haupt
View graph of relations
In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed.
Original languageEnglish
JournalHuman Vaccines
Volume5
Issue number10
Pages (from-to)696-704
Number of pages9
ISSN1554-8600
Publication statusPublished - 1 Oct 2009

ID: 32315413